BioSpace News Archive

BioMidwest

Boehringer Ingelheim Release: Jardiance Reduced Risk of Cardiovascular Death in Adults With Type 2 Diabetes and Peripheral Artery Disease

hese results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly at the AHA Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online in the AHA’s journal, Circulation.

November 13, 2017

·

13 min read

Business

Prometic Reports 2017 Third Quarter Highlights and Financial Results

Total revenues for the third quarter ended September 30, 2017 were $24M compared to $3.7M for the third quarter ended September 30, 2016.

November 13, 2017

·

10 min read

Drug Development

Boehringer Ingelheim’s New RE-VERSE AD Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind) in Pradaxa Patients With GI Bleeding or Needing Emergency Surgery

The analyses provide further insights on the use of idarucizumab in patients with GI bleeding and in those with a need for urgent surgery or intervention.

November 13, 2017

·

13 min read

Business

MediWound to Host Third Quarter 2017 Financial Results Conference Call on November 16, 2017 at 8:30 a.m. Eastern Time

Following the release, MediWound’s management will host a conference call for the investment community beginning at 8:30 a.m.

November 13, 2017

·

4 min read

Genetown

Voyager Therapeutics Announces Closing of Public Offering of Common Stock

The aggregate net proceeds before expenses to Voyager from the offering are approximately $58.4 million, after deducting underwriting discounts and commissions.

November 13, 2017

·

4 min read

BioMidwest

ARKRAY USA Announces the Availability of the GLUCOCARD Shine XL Blood Glucose Monitoring System

ARKRAY USA, a leader in diabetes care products, announced today that the GLUCOCARD Shine XL, ARKRAY’s newest BGMS, is now being shipped to customers in the U.S.

November 13, 2017

·

1 min read

Genetown

eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association

Results from the study were highlighted in a poster presentation on November 13 at the American Heart Association Scientific Sessions 2017, in Anaheim, California.

November 13, 2017

·

3 min read

Drug Development

Novartis Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity In nAMD, a Leading Cause of Blindness.

The results of the head-to-head trials, HAWK and HARRIER, were presented at the American Academy of Ophthalmology 2017 Annual Meeting

November 13, 2017

·

14 min read

BioCapital

QIAGEN Celebrates Surpassing 2,000 Cumulative Placements of QIAsymphony

QIAGEN N.V. today announced the 2,000th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories worldwide.

November 13, 2017

·

1 min read

Amgen Leaps Into the World of Regenerative Medicin

Drug Development

Amgen’s New Analyses Show Repatha Significantly Reduced Cardiovascular Events in Patients With Peripheral Artery Disease and in Patients With a History of Heart Attacks

These results highlight Repatha’s ability to reduce the residual risk for CV events particularly in high-risk patients with limited treatment options.

November 13, 2017

·

18 min read